Solvay S.A.

Content

• Chapter 1 Executive Summary
  • Key Findings
  • Historical And Forecast Prescription Pharmaceutical Sales Performance
  • Therapeutic Strategy
  • Launch And Expiry Outlook
  • Externalization, Geographic And Molecule Type Strategies
  • Externalization Strategy
  • Geographic Strategy
  • Molecule Type Strategy
  • Swot Analysis
• Chapter 2 Corporate History
  • Key Findings
  • Background
  • Key Corporate Developments
  • M&A History
  • Neopharma
  • Fournier
  • Current Corporate Structure
  • Pharmaceuticals
  • Chemicals
  • Plastics
  • Current Management Team
• Chapter 3 Historical Performance
  • Key Findings
  • Introduction
  • Revenue And Growth Rate Analysis, 2001-06
  • Revenue And Growth Rate Vs. Peer Set
  • Product Analysis, 2001-06
  • Growth Drivers
  • Tricor
  • Androgel
  • Betaserc
  • Growth Resistors
  • Estratest
  • Operating Revenue And Cost Analysis, 2001-06
  • Operating Revenue/Cost Analysis
• Chapter 4 Forecast Performance
  • Key Findings
  • Introduction
  • Revenue And Growth Rate, 2006-12
  • Product Analysis, 2006-12
  • Growth Drivers
  • Androgel
  • Tricor
  • Duodopa
  • Slv-308
  • Growth Resistors
  • Estratest
  • Marinol
  • Key Strategic Products
  • Therapy Area Analysis, 2006-12
  • Cardiovascular
  • Urology & Sexual Health
  • Cns
  • Oncology
  • Therapy Area Focus
  • Launches And Expiries Analysis, 2006-12
  • Launch Portfolio
  • Bifeprunox Delays Hit Launch Sales
  • New Cardiovascular Products Will Struggle To Gain Market Share
  • Discontinuations Have Resulted In Reduced 'Launch' Sales
  • Core Portfolio
  • Expiry Portfolio
  • Launch/Core/Expiry Configuration
  • Externalization Analysis, 2006-12
  • Geographic Analysis, 2006-12
  • Molecule Type Analysis, 2006-12
• Chapter 5 Key Products And Competitors
  • Key Findings
  • Overview
  • Urology & Sexual Health
  • Androgel
  • Overview
  • Sales Forecast
  • Newsflow
  • Competitive Landscape
  • Future Market Assessment
  • Cns
  • Bifeprunox
  • Overview
  • Sales Forecast
  • Newsflow
  • Competitive Landscape
  • Future Market Assessment
  • Cardiovascular
  • Tricor
  • Overview
  • Sales Forecast
  • Newsflow
  • Competitive Landscape
  • Future Market Assessment
  • Zolip (Simvastatin + Fenofibrate)
  • Oncology
  • Marinol
  • Overview
  • Sales Forecast
  • Newsflow
  • Competitive Landscape
  • Future Market Assessment
  • Gastrointestinal
  • Creon
  • Overview
  • Sales Forecast
  • Newsflow
  • Competitive Landscape
  • Future Market Assessment
  • R&D Pipeline
• Chapter 6 Appendix
  • Ims Vs. Company-Reported Data Reconciliation
  • Abbreviations
  • Exchange Rates
• List of Tables
  • Table 1: Solvay Group Corporate Executive Committee
  • Table 2: Peer Set Overview
  • Table 3: Operating Revenue/Cost Analysis ($M), 2001-06
  • Table 4: Operating Cost Ratio Analysis (% of Total Revenues), 2001-06
  • Table 5: Product Portfolio Overview, Sales ($M), 2006-12
  • Table 6: Therapy Area Overview, Sales ($M), 2006-12
  • Table 7: Launch Portfolio Overview, Sales ($M), 2006-12
  • Table 8: Core Portfolio Overview, Sales ($M), 2006-12
  • Table 9: Expiry Portfolio Overview, Sales ($M), 2006-12
  • Table 10: Externally Developed Portfolio ($M), 2006-12
  • Table 11: Molecule Type Overview, Sales ($M), 2006-12
  • Table 12: Key Products Overview
  • Table 13: Androgel: Overview
  • Table 14: Androgel: Sales Forecast ($M), 2006-12
  • Table 15: Androgel: Newsflow
  • Table 16: Bifeprunox: Overview
  • Table 17: Bifeprunox: Sales Forecast ($M), 2006-12
  • Table 18: Bifeprunox: Newsflow
  • Table 19: Tricor: Overview
  • Table 20: Tricor: Sales Forecast ($M), 2006-12
  • Table 21: Tricor: Newsflow
  • Table 22: Us Antidyslipidemic Sales, 2006
  • Table 23: Marinol: Overview
  • Table 24: Marinol: Sales Forecast ($M), 2006-12
  • Table 25: Marinol: Newsflow
  • Table 26: Creon: Overview
  • Table 27: Creon: Sales Forecast ($M), 2006-12
  • Table 28: Creon: Newsflow
  • Table 29: Solvay's R&D Pipeline (Phase I-Registration)
  • Table 30: Solvay's Indication Broadening Pipeline (Phase I-Registration)
  • Table 31: Exchange Rates, 2006
• List of Figures
  • Figure 1: Historical And Forecast Prescription Pharmaceutical Sales Performance (% Cagr), Solvay And Mid Pharma Peer Set
  • Figure 2: Therapeutic Focus Vs. Mid Pharma Peer Set (%), 2006
  • Figure 3: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % of 2006 Sales), Solvay
  • Figure 4: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % of 2006 Sales), Peer Set
  • Figure 5: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2006
  • Figure 6: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2012
  • Figure 7: Swot Analysis of Solvay
  • Figure 8: M&A/Divestment History
  • Figure 9: Current Corporate Structure
  • Figure 10: Revenue & Growth Rate (Prescription Pharmaceutical Sales) ($M), 2001-06
  • Figure 11: Prescription Pharmaceutical Revenue ($M) And Growth Rate (%) Vs. Peer Set, 2001-06
  • Figure 12: Growth Drivers/Resistor Products of Historical Revenue Performance ($M), 2001-06
  • Figure 13: Operating Revenue/Cost Analysis ($M), 2001-06
  • Figure 14: Operating Cost Ratio Analysis (% of Total Revenues), 2001-06
  • Figure 15: Prescription Pharmaceutical Revenue ($M) And Growth Rate (%), 2006-12
  • Figure 16: Top Five Products By Sales ($M), 2006
  • Figure 17: Top Five Products By Sales ($M), 2012
  • Figure 18: Growth Drivers And Resistors By Product, 2006-12
  • Figure 19: Key Strategic Products, Sales ($M), 2006-12
  • Figure 20: Prescription Pharmaceutical Sales By Therapy Area ($M), 2006-12
  • Figure 21: Growth Drivers And Resistors By Therapy Area ($M), 2006-12
  • Figure 22: Prescription Pharmaceutical Sales By Therapy Area (%), 2006-12
  • Figure 23: Therapy Area Focus Compared With Peer Set (% Total Prescription Pharmaceutical Sales), 2006
  • Figure 24: Therapy Area Focus Compared With Peer Set (% Total Prescription Pharmaceutical Sales), 2012
  • Figure 25: Launch Schedule, Sales ($M), 2006-12
  • Figure 26: Core Products Sales Growth ($M), 2006-12
  • Figure 27: Expiry Schedule, Sales ($M), 2006-12
  • Figure 28: Launch, Core And Expiry, Sales ($M), 2006-12
  • Figure 29: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % of 2006 Sales), Solvay
  • Figure 30: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % of 2006 Sales), Peer Set
  • Figure 31: Externalization Dependency, Sales ($M), 2006-12
  • Figure 32: Growth Drivers And Resistors, Externally Vs. Internally Discovered Products, Sales ($M), 2006-12
  • Figure 33: Externalization Dependency Vs. Peer Set, % Total Sales, 2006
  • Figure 34: Externalization Dependency Vs. Peer Set, % Total Sales, 2012
  • Figure 35: Geographical Sales Breakdown ($M), 2006-12
  • Figure 36: Growth Drivers And Resistors By Geography, Sales ($M), 2006-12
  • Figure 37: Us Dependency Vs. Peer Set, % Total Sales, 2006
  • Figure 38: Us Dependency Vs. Peer Set, % Total Sales, 2012
  • Figure 39: Molecule Type Sales Breakdown ($M), 2006-12
  • Figure 40: Growth Drivers And Resistors By Molecule Type, Sales ($M), 2006-12
  • Figure 41: Biologics Dependency Vs. Peer Set, % Total Sales, 2006
  • Figure 42: Biologics Dependency Vs. Peer Set, % Total Sales, 2012
  • Figure 43: Androgen Class Quarterly Us Market Share By Sales, 2002-07
  • Figure 44: Ims Vs. Company-Reported Ethical Sales Discrepancy ($M), 2006
  • Figure 45: Ims Vs. Company-Reported Ethical Sales Forecast Growth Rates (%), 2006-12